Antengene announced receipt of a USD 60 million upfront payment from UCB. The cash infusion strengthens Antengene’s liquidity and supports the advancement of its therapeutic programs. Who is involved: Antengene Corporation Limited (SEHK: 6996.HK) and UCB (Belgian biopharmaceutical company).. Likely next: Antengene will likely allocate the funds to R&D milestones, while UCB may trigger additional payments upon achievement of predefined development targets.. Antengene Corporation Limited announced on July 13 2026 that it has received a USD 60 million upfront payment from Belgian biopharma UCB. The payment is tied to an undisclosed collaboration and provides immediate financing for Antengene’s research and development activities. While the financial boost is clear, the specific assets or milestones attached to the tranche were not disclosed in the release. Sectors affected: Biotechnology Pharmaceutical
INTELLIGENCE
Social Pulse
AI estimate · not scraped